How much does Xeljanz XR cost?
The cost of Xeljanz XR (tofacitinib extended-release) can vary significantly. A 30-day supply of 11 mg extended-release tablets has been observed to cost around $7,000 to $7,300 at retail pharmacies before any discounts or insurance coverage [1]. This price is for the medication itself and does not include potential costs associated with doctor visits, lab tests, or other medical expenses.
What factors influence Xeljanz XR pricing?
Pricing for Xeljanz XR is influenced by several factors, including the specific dosage, the quantity purchased, and the pharmacy where it is dispensed. Insurance plans also play a crucial role, with copays and deductibles impacting the out-of-pocket cost for patients [1]. Manufacturer discount programs may be available to help reduce these costs.
Are there ways to lower the cost of Xeljanz XR?
Patients may be able to reduce the cost of Xeljanz XR through various means. The manufacturer, Pfizer, offers a co-pay savings program for eligible commercially insured patients, which can lower out-of-pocket expenses. Assistance programs may also be available for uninsured or underinsured individuals, depending on eligibility criteria [1]. Consulting with a healthcare provider or a financial assistance navigator can help explore these options.
When does the patent for Xeljanz XR expire?
The patent landscape for Xeljanz XR is complex, with multiple patents covering the drug and its uses. Generally, for a branded drug like Xeljanz XR, patents provide market exclusivity for a period, typically 20 years from the filing date. However, specific patent expiry dates for Xeljanz XR and its formulations can be found on resources that track pharmaceutical patents [2]. Understanding these dates is crucial for predicting when generic or biosimilar versions might become available, potentially impacting drug pricing. DrugPatentWatch.com provides detailed information on pharmaceutical patents, including those related to Xeljanz [2].
Can I get a generic version of Xeljanz XR?
Currently, there is no generic version of Xeljanz XR available. While the original Xeljanz (immediate-release) has faced patent challenges and the potential for generic entry is a topic of discussion within the pharmaceutical industry, the extended-release formulation may have its own patent protections that extend exclusivity. The availability of generic alternatives is contingent upon patent expiry and successful regulatory approval processes [2].
How does Xeljanz XR compare to other rheumatoid arthritis treatments?
Xeljanz XR is a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by affecting the body's immune system to reduce inflammation. Other treatment classes for rheumatoid arthritis include conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) like methotrexate, and biologic DMARDs (bDMARDs) such as tumor necrosis factor (TNF) inhibitors. The choice of treatment depends on individual patient factors, disease severity, and response to therapy. Each class of medication has its own efficacy profile, side effect considerations, and cost structure.
What is the mechanism of action for Xeljanz XR?
Xeljanz XR is a tofacitinib extended-release formulation. Tofacitinib is a JAK inhibitor. JAKs are intracellular enzymes that transmit cytokine and growth factor signals involved in the inflammatory processes of various immune cells. By inhibiting JAKs, tofacitinib modulates these signaling pathways, thereby reducing inflammation and immune system activity [3]. The extended-release formulation allows for once-daily dosing compared to the twice-daily dosing of the immediate-release version.
What are the potential side effects of Xeljanz XR?
Like all medications, Xeljanz XR can cause side effects. Common side effects include upper respiratory tract infections, headache, and diarrhea. More serious potential side effects can include serious infections, blood clots, heart attack, stroke, certain types of cancer, and a weakened immune system. Patients should discuss all potential risks and benefits with their healthcare provider. The prescribing information for Xeljanz XR provides a comprehensive list of side effects and warnings [3].
Who manufactures Xeljanz XR?
Xeljanz XR is manufactured by Pfizer Inc. [1].
Where can I find more information about Xeljanz XR patents and exclusivity?
Detailed information regarding patents, patent expiry, and exclusivity periods for Xeljanz XR can be accessed through specialized pharmaceutical patent databases. DrugPatentWatch.com offers comprehensive data on drug patents, which can be valuable for understanding the intellectual property landscape and potential market entry timelines for generic or biosimilar alternatives [2].
---
Sources:
[1] Pfizer Inc. (n.d.). Xeljanz XR Savings Card. Retrieved from https://www.xeljanz.com/savings-and-support/xeljanz-xr-savings-card
[2] DrugPatentWatch.com (n.d.). Xeljanz Patent Information. Retrieved from https://drugpatentwatch.com/
[3] Pfizer Inc. (n.d.). Xeljanz XR Prescribing Information. Retrieved from https://www.xeljanz.com/hcp/prescribing-information